Publications by authors named "Peter Linde"

Claim this Profile
I
Identification of Antibodies to Chondrocyte and Synoviocyte Antigens in Equine Osteoarthritis.
Peter Linde, Jade Kurihara, Lyndah Chow, Zoë J Williams, Dean Hendrickson

J Orthop Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate immune pathway activation to modulate mesenchymal stromal cell (MSC) interactions with synovium and cartilage.
Peter Linde, Lyndah Chow, Isabella Sabino, Zoë Williams, Renata Impastato

Front Bioeng Biotechnol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adult ovine connective tissue cells resemble mesenchymal stromal cells in their propensity for extensive ex vivo expansion.
Peter E Linde, Christian M Puttlitz, John D Kisiday

Connect Tissue Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High throughput computational evaluation of how scaffold architecture, material selection, and loading modality influence the cellular micromechanical environment in tissue engineering strategies.
Mitchell I Page, Peter E Linde, Christian M Puttlitz

JOR Spine· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational modeling to predict the micromechanical environment in tissue engineering scaffolds.
Mitchell I Page, Peter E Linde, Christian M Puttlitz

J Biomech· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Marc Humbert, Vallerie McLaughlin, J Simon R Gibbs, Mardi Gomberg-Maitland, Marius M Hoeper, Peter G Linde

N Engl J Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Ana Carolina Giuseppi, Jeevan Shetty, Peter G Linde

J Clin Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Stephen E Maxwell, Priya Sriraman, Peter G Linde

CPT Pharmacometrics Syst Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
M Domenica Cappellini, Vip Viprakasit, Ali T Taher, Pencho Georgiev, Kevin H M Kuo, Peter G Linde

N Engl J Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Pierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, Guillermo Garcia-Manero, Rena Buckstein, Peter G Linde

N Engl J Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.
Justyna Siwy, Petra Zürbig, Angel Argiles, Joachim Beige, Marion Haubitz, Peter G Linde

Nephrol Dial Transplant· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrolysis-Driven and Pressure-Controlled Diffusive Growth of Successive Bubbles on Microstructured Surfaces.
Peter van der Linde, Álvaro Moreno Soto, Pablo Peñas-López, Javier Rodríguez-Rodríguez, Detlef Lohse

Langmuir· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
Nicholas J A Webb, Gary Lerner, Bradley A Warady, Katherine M Dell, Larry A Greenbaum, Peter Linde

Pediatr Nephrol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.
Peter G Linde, Patrick Archdeacon, Matthew D Breyer, Tod Ibrahim, Jula K Inrig

J Am Soc Nephrol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insertion Process of Ceramic Nanoporous Microneedles by Means of a Novel Mechanical Applicator Design.
Xavier H M Hartmann, Peter van der Linde, Erik F G A Homburg, Lambert C A van Breemen, Arthur M de Jong

Pharmaceutics· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Tadao Akizawa, Takashi Akiba, Hideki Hirakata, Eriko Kinugasa, Yoshihiro Tominaga, Peter G Linde

Ther Apher Dial· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Melanie P Chin, Scott A Reisman, George L Bakris, Megan O'Grady, Peter G Linde

Am J Nephrol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Melanie P Chin, Danielle Wrolstad, George L Bakris, Glenn M Chertow, Dick de Zeeuw, Peter G Linde

J Card Fail· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Hiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, Paul Audhya, George L Bakris, Peter Linde

Nephrol Dial Transplant· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microwave Ablation in Mitral Valve Surgery for Atrial Fibrillation (MAMA).
Anders Jönsson, Mika Lehto, Henrik Ahn, Ulf Hermansson, Peter Linde

J Atr Fibrillation· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atrial function after epicardial microwave ablation in patients with atrial fibrillation.
Anders Ahlsson, Peter Linde, Peter Rask, Anders Englund

Scand Cardiovasc J· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
Mandeep R Mehra, Ted McCluskey, Mark Barr, Robert C Bourge, Mariell L Jessup, Peter Linde

Am Heart J· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis